Liz Barrett, a Leader and Builder in US HealthTech, has served as CEO of UroGen Pharma since January 2019. With prior leadership roles at Novartis, Pfizer, and J&J, she brings extensive experience to UroGen, a biotech firm revolutionizing treatments for specialty cancers and urologic diseases. Barrett led UroGen in bringing Jelmyto®, the first FDA-approved treatment for low-grade Upper Tract Urothelial Cancer, to market, showcasing her commitment to impactful healthcare solutions.
666 3rd Ave, 6th Floor, New York, NY 10017